Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY): a multicentre, double-blind, placebo-controlled, randomised withdrawal phase 3 trial

Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trial

(2021) Kristian Reich et al.   LANCET

Bimekizumab for patients with moderate-to-severe plaque psoriasis: 60-week results from BE ABLE 2, a randomized, double-blinded, placebo-controlled phase 2b extension study

(2020) Andrew Blauvelt et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Efficacy and Safety of Continuous Risankizumab Therapy vs Treatment Withdrawal in Patients With Moderate to Severe Plaque Psoriasis

(2020) Andrew Blauvelt et al.   JAMA Dermatology

Bimekizumab, a Novel Humanized IgG1 Antibody That Neutralizes Both IL-17A and IL-17F

(2020) Ralph Adams et al.   Frontiers in Immunology

Development and Content Validation of the Psoriasis Symptoms and Impacts Measure (P-SIM) for Assessment of Plaque Psoriasis

(2020) Alice B. Gottlieb et al.   Dermatology and Therapy

Guselkumab efficacy after withdrawal is associated with suppression of serum IL-23-regulated IL-17 and IL-22 in psoriasis: VOYAGE 2 study

(2019) Kenneth B. Gordon et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

A head-to-head comparison of the efficacy and safety of ixekizumab and adalimumab in biological-naïve patients with active psoriatic arthritis: 24-week results of a randomised, open-label, blinded-assessor trial

(2019) Philip J Mease et al.   ANNALS OF THE RHEUMATIC DISEASES

Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): results from a phase 3, randomised controlled trial

(2019) Kristian Reich et al.   LANCET

A head‐to‐head comparison of ixekizumab vs. guselkumab in patients with moderate‐to‐severe plaque psoriasis: 12‐week efficacy, safety and speed of response from a randomized, double‐blinded trial

(2019) A. Blauvelt et al.   BRITISH JOURNAL OF DERMATOLOGY

Dual neutralization of both interleukin 17A and interleukin 17F with bimekizumab in patients with psoriasis: Results from BE ABLE 1, a 12-week randomized, double-blinded, placebo-controlled phase 2b trial

(2018) Kim A. Papp et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Interleukin 23 in the skin: role in psoriasis pathogenesis and selective interleukin 23 blockade as treatment

(2018) Tom C. Chan et al.   Therapeutic Advances in Chronic Disease

The Immunologic Role of IL-17 in Psoriasis and Psoriatic Arthritis Pathogenesis

(2018) Andrew Blauvelt et al.   CLINICAL REVIEWS IN ALLERGY & IMMUNOLOGY

Biological Properties and the Role of IL-25 in Disease Pathogenesis

(2018) Yuwan Liu et al.   Journal of Immunology Research

Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate-to-severe plaque psoriasis up to 1 year: Results from the CLEAR study

(2017) Andrew Blauvelt et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Continuous dosing versus interrupted therapy with ixekizumab: an integrated analysis of two phase 3 trials in psoriasis

(2017) A. Blauvelt et al.   JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY

Adherence and dosing interval of subcutaneous antitumour necrosis factor biologics among patients with inflammatory arthritis: analysis from a Canadian administrative database

(2017) Peter Bhoi et al.   BMJ Open

Secukinumab: a review of the anti-IL-17A biologic for the treatment of psoriasis

(2017) Jillian Frieder et al.   Therapeutic Advances in Chronic Disease

Dosing Frequency and Medication Adherence in Chronic Disease

(2016) Craig I. Coleman et al.   JOURNAL OF MANAGED CARE PHARMACY

Differential Drug Survival of Biologic Therapies for the Treatment of Psoriasis: A Prospective Observational Cohort Study from the British Association of Dermatologists Biologic Interventions Register (BADBIR)

(2015) Richard B. Warren et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

Treatment patterns with etanercept and adalimumab for psoriatic diseases in a real-world setting

(2013) Machaon Bonafede et al.   JOURNAL OF DERMATOLOGICAL TREATMENT

Keratinocyte Overexpression of IL-17C Promotes Psoriasiform Skin Inflammation

(2013) A. Johnston et al.   JOURNAL OF IMMUNOLOGY

Effect of IL-17A blockade with secukinumab in autoimmune diseases

(2012) Dhavalkumar D Patel et al.   ANNALS OF THE RHEUMATIC DISEASES

Off-Label Biologic Regimens in Psoriasis: A Systematic Review of Efficacy and Safety of Dose Escalation, Reduction, and Interrupted Biologic Therapy

(2012) Elizabeth A. Brezinski et al.   PLoS One